Vision connects us to the world
Featured
This document is a corporate presentation for Kodiak, an ophthalmology medicines company, dated September 2026.
September 2026 corporate presentation. Retina focused company with THREE LATE-STAGE PROGRAMS built on the ABC Platform.
Interactive corporate profile. Covering the ABC platform and the Zenkuda, KSI-501 and KSI-101 clinical programs.
Enrollment complete in the first 300-patient cohort of Phase 3 PEAK (KSI-101, MESI). TOPLINE DATA expected DECEMBER 2026.
POSITIVE GLOW2 Phase 3 results: Zenkuda™ dosed every 6 months, 62.5% ≥2-step DRSS improvement vs 3.3% sham. BLA-READY profile.
